Ignite Creation Date:
2025-12-25 @ 3:01 AM
Ignite Modification Date:
2025-12-31 @ 6:17 PM
Study NCT ID:
NCT04486833
Status:
RECRUITING
Last Update Posted:
2025-11-05
First Post:
2020-07-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Sponsor:
Genprex, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Carcinoma, Non-Small Cell Lung | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Epidermal growth factor receptor mutation (EGFR) | View |
| None | osimertinib | View |
| None | Tumor suppressor gene 2 (TUSC2) | View |
| None | Lipid nanoparticle (LNP) | View |
| None | Gene therapy | View |
| None | Tagrisso | View |
| None | FUS1-nanoparticles | View |
| None | NSCLC | View |
| None | Reqorsa | View |
| None | quaratusugene ozeplasmid | View |